InvestorsHub Logo
Followers 11
Posts 617
Boards Moderated 0
Alias Born 02/06/2019

Re: None

Wednesday, 12/09/2020 11:46:30 AM

Wednesday, December 09, 2020 11:46:30 AM

Post# of 2794
New PR from ATNM... this comment in the write up caught my attention. Is this field really growing as they imply, ie, not a niche market, and saying they are the 'leader' rather than just one of the 'players' in this sector??
hadn't ever thought of them being a buyout candidate before this was said... ok, back to my regularly scheduled program of seeing them complete their PH 3...

https://ir.actiniumpharma.com/press-releases/detail/384

"Targeted radiotherapy is witnessing a renaissance driven by strong clinical data emerging in multiple indications. This has resulted in acquisitions, new company formation and investments in new targets to pursue with radiotherapy," said Sandesh Seth, Actinium's Chairman and CEO. He continued, "Actinium is proud to have not only established ourselves as a leader in the targeted radiotherapy field and is the only company pursuing well validated targets in hematology with late stage clinical programs.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ATNM News